News & Events
Beyond the Hype: The Real Bottlenecks in Breast Cancer Innovation
A Deep Dive into the Current Landscape of SERDs, ADCs, and Precision Oncology The pace of breast cancer drug development has never been faster. From the practice-changing durability of oral selective estrogen receptor degraders (SERDs)
AccuGenomics and 1Cell.Ai Partner to Bring Ultra-Sensitive Liquid Biopsy Testing Across Asia, with Plans for U.S. Expansion
Collaboration integrates per-sample NGS internal standards with multi-omic precision oncology platform to enhance cancer diagnostics accuracy and access WILMINGTON, N.C. and MUMBAI, India, Oct. 13, 2025 /PRNewswire/ — AccuGenomics, Inc., a US-based leader in next-generation sequencing (NGS)
Join Us at SABCS – San Antonio, TX | December 9–12
Booth #1446 – Discover our latest breast cancer research and AI-driven insights shaping precision oncology. Plan Your Visit to SABCS
Join Us at World ADC – San Diego, CA | November 5–6
Booth #86 – See how 1Cell.Ai technology supports translational research and biomarker validation for next-generation ADC programs. Visit Us at World ADC
Join Us at ISLB 2025 – Orlando, FL | November 1–3
Booth #307 – Learn how live single circulating tumor cell capture is redefining biomarker discovery and precision oncology. Poster PresentationPP.36: (111) — ctDNA clearance of epigenetic regulators and HRR mutations predicts immunotherapy response in advanced